Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2900 - Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)


11 Sep 2017


Poster display session


Breast Cancer


Javier Pascual


Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364


J. Pascual1, B. Rojas-Garcia1, V. Peg2, S. Diaz-Botero3, E. Zamora1, E. Muñoz Couselo1, M. Oliveira1, P. Gomez Pardo1, J. Perez Garcia1, F. Ruiz-Pace4, C. VIAPLANA4, S. Escrivá1, L. Garrigos1, M. Arumi1, M. Espinosa-Bravo3, J. Cortés5, I. Rubio3, C. Saura1, R. Dienstmann4, M. Bellet Ezquerra1

Author affiliations

  • 1 Medical Oncology Department, Vall d’Hebron University Hospital Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Anatomical Pathology, Vall d'Hebron University Hospital, Barcelona/ES
  • 3 Breast Pathology Unit, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Oncology Data Science Group (odyssey), Vall d'Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 5 Medical Oncology Department, Vall d’Hebron University Hospital Institute of Oncology (VHIO), 08035 - barcelona/ES


Abstract 2900


Pathologic complete response (pCR) and residual cancer burden (RCB) after NAC are validated prognostic markers in BC. We assessed the impact of adding Ki-67% drop (baseline biopsy - surgery) to distant metastasis relapse-free survival (dRFS) models containing CP factors plus post-treatment stage (MDACC CPS score), estrogen receptor status and tumor grade (MDACC CPS+EG score).


Records from 341 patients (pts) with lumB/HER2 neg (baseline Ki67 >20%) or TNBC who received NAC from 2008 to 2015 at our hospital were reviewed. Uni- and multivariate Cox models were constructed and concordance-index (c-index) calculated.


Pts: median age 47 years (24-83), 60% lumB and 40% TNBC, 62% stage 2, 38% stage 3. pCR: 12% lumB, 32% TNBC (p 


Our data support the addition of Ki-67% drop after NAC in lumB and TNBC to existing dRFS online outcome calculators. In the context of RCB 2/3, Ki-67 > = 20% drop is mainly seen in lumB/HER neg tumors. Importantly, Ki-67 < 20% drop identifies a high-risk population that may be eligible to clinical trials with novel therapeutic interventions in the adjuvant setting.

Clinical trial identification

Legal entity responsible for the study

Vall d'Hebron University Hospital


Vall d'Hebron Institute of Oncology


M. Oliveira: Consulting or Advisory Role in Roche-Genentech and Puma Biotechnology. Research Funding in AstraZeneca and Genentech/Roche. R. Dienstmann: Consulting or Advisory Role in Roche-Genentech and in Astellas Pharma. Research Funding in Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.